Prednisolone improves the response to primary endocrine treatment for advanced breast cancer - PubMed (original) (raw)

Clinical Trial

Prednisolone improves the response to primary endocrine treatment for advanced breast cancer

R D Rubens et al. Br J Cancer. 1988 Nov.

Free PMC article

Abstract

Two hundred and twenty patients with progressive advanced breast cancer were given primary endocrine treatment (PET) according to menstrual status. Pre-menopausal patients received ovarian irradiation (O) and post-menopausal tamoxifen 10 mg bd (T). Patients were randomised to receive either no additional treatment or prednisolone 5 mg bd (P). Similar results were observed in each menstrual subgroup. In 194 evaluable patients, the response to PET + P was 49% and to PET alone 30% (P less than 0.01). P increased the median duration of response from 9 to 14 months (P less than 0.002) and the median time to disease progression from 5 to 9 months (P less than 0.001). Response to P after O or T alone occurred in only 2/62 (3%). Median survival in patients randomised to receive P at the outset of PET was prolonged by 4 months (P less than 0.05). The addition of P significantly improves the response to O or T in the treatment of advanced breast cancer.

PubMed Disclaimer

Comment in

• Prednisolone enhancement of primary endocrine anticancer treatment: a possible anti-angiogenic effect.
  Beranek JT. Beranek JT. Br J Cancer. 1989 Jul;60(1):149. doi: 10.1038/bjc.1989.238. Br J Cancer. 1989. PMID: 2478179 Free PMC article. No abstract available.

Similar articles

• Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer.
  Stewart JF, Rubens RD, King RJ, Minton MJ, Steiner R, Tong D, Winter PJ, Knight RK, Hayward JL. Stewart JF, et al. Eur J Cancer Clin Oncol. 1982 Dec;18(12):1307-14. doi: 10.1016/0277-5379(82)90134-1. Eur J Cancer Clin Oncol. 1982. PMID: 6891929 Clinical Trial.
• Effects of prednisolone on sex hormone binding globulin during primary endocrine treatment of advanced breast cancer.
  Wang DY, Rubens RD, Clark GM, Moore JW, Bulbrook RD. Wang DY, et al. Breast Cancer Res Treat. 1988 Apr;11(1):67-70. doi: 10.1007/BF01807560. Breast Cancer Res Treat. 1988. PMID: 3382764 Clinical Trial.
• Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer.
  Blackburn AM, Wang DY, Bulbrook RD, Thomas BS, Kwa HG, Hoare SA, Rubens RD. Blackburn AM, et al. Cancer Treat Rep. 1984 Dec;68(12):1447-53. Cancer Treat Rep. 1984. PMID: 6239689 Clinical Trial.
• Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause.
  Nourmoussavi M, Pansegrau G, Popesku J, Hammond GL, Kwon JS, Carey MS. Nourmoussavi M, et al. Cancer Treat Rev. 2017 Apr;55:26-35. doi: 10.1016/j.ctrv.2017.02.005. Epub 2017 Feb 22. Cancer Treat Rev. 2017. PMID: 28288389 Review.
• [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
  Mauriac L, Blanc-Vincent MP, Luporsi E, Cutuli B, Fourquet A, Garbay JR, Giard S, Spyratos F, Zafrani B, Dilhuydy JM. Mauriac L, et al. Bull Cancer. 2000 Jun;87(6):469-90. Bull Cancer. 2000. PMID: 10903789 Review. French.

Cited by

• Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy.
  Keith BD. Keith BD. BMC Cancer. 2008 Mar 28;8:84. doi: 10.1186/1471-2407-8-84. BMC Cancer. 2008. PMID: 18373855 Free PMC article. Review.
• Prednisolone enhancement of primary endocrine anticancer treatment: a possible anti-angiogenic effect.
  Beranek JT. Beranek JT. Br J Cancer. 1989 Jul;60(1):149. doi: 10.1038/bjc.1989.238. Br J Cancer. 1989. PMID: 2478179 Free PMC article. No abstract available.
• Combination anastrozole and fulvestrant in metastatic breast cancer.
  Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Mehta RS, et al. N Engl J Med. 2012 Aug 2;367(5):435-44. doi: 10.1056/NEJMoa1201622. N Engl J Med. 2012. PMID: 22853014 Free PMC article. Clinical Trial.
• A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer.
  Fentiman IS, Howell A, Hamed H, Lee SM, Ranson M, Wall J, Chaudary MA, Ash CM, Gregory WM, Sellwood RA, et al. Fentiman IS, et al. Br J Cancer. 1994 Oct;70(4):729-31. doi: 10.1038/bjc.1994.384. Br J Cancer. 1994. PMID: 7917929 Free PMC article. Clinical Trial.

References

1. 1. Br J Cancer. 1977 Mar;35(3):292-8 - PubMed
2. 1. Can Med Assoc J. 1979 May 19;120(10):1221-9 - PubMed
3. 1. Cancer. 1981 Aug 15;48(4):883-7 - PubMed
4. 1. Breast Cancer Res Treat. 1982;2(3):243-50 - PubMed
5. 1. Eur J Cancer Clin Oncol. 1982 Dec;18(12):1307-14 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Medical

  • MedlinePlus Health Information